Bicocca Open Archive

Logo unimib boa
LAPADULA, GIUSEPPE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.590
AS - Asia 9.612
EU - Europa 6.410
SA - Sud America 1.547
Continente sconosciuto - Info sul continente non disponibili 777
AF - Africa 241
OC - Oceania 10
Totale 32.187
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.699
SG - Singapore 3.515
IT - Italia 2.031
VN - Vietnam 1.727
HK - Hong Kong 1.418
CN - Cina 1.395
BR - Brasile 1.121
RU - Federazione Russa 1.016
CA - Canada 671
SE - Svezia 662
DE - Germania 610
IE - Irlanda 576
BD - Bangladesh 327
FR - Francia 322
GB - Regno Unito 279
IN - India 254
UA - Ucraina 183
FI - Finlandia 162
ID - Indonesia 157
AR - Argentina 143
AT - Austria 137
MX - Messico 115
NL - Olanda 109
KR - Corea 106
TR - Turchia 106
IQ - Iraq 94
ZA - Sudafrica 77
EC - Ecuador 72
JP - Giappone 69
PK - Pakistan 67
PH - Filippine 64
CO - Colombia 60
SA - Arabia Saudita 59
ES - Italia 55
PL - Polonia 51
RO - Romania 49
VE - Venezuela 48
UZ - Uzbekistan 39
MA - Marocco 36
DK - Danimarca 30
CL - Cile 28
PY - Paraguay 26
KE - Kenya 23
MY - Malesia 23
CZ - Repubblica Ceca 22
JM - Giamaica 22
BE - Belgio 20
JO - Giordania 20
TN - Tunisia 20
ET - Etiopia 19
UY - Uruguay 18
AL - Albania 17
CR - Costa Rica 17
LT - Lituania 17
PE - Perù 17
KZ - Kazakistan 16
AE - Emirati Arabi Uniti 15
IR - Iran 15
NP - Nepal 15
HN - Honduras 14
DZ - Algeria 13
TH - Thailandia 13
TT - Trinidad e Tobago 13
CH - Svizzera 12
EG - Egitto 12
OM - Oman 12
IL - Israele 10
PA - Panama 10
BO - Bolivia 9
LB - Libano 9
AU - Australia 8
BH - Bahrain 8
PS - Palestinian Territory 8
AZ - Azerbaigian 7
GE - Georgia 7
MD - Moldavia 7
GR - Grecia 6
LY - Libia 6
PT - Portogallo 6
SN - Senegal 6
SY - Repubblica araba siriana 6
TW - Taiwan 6
GT - Guatemala 5
LV - Lettonia 5
NG - Nigeria 5
AM - Armenia 4
BG - Bulgaria 4
DO - Repubblica Dominicana 4
EE - Estonia 4
HU - Ungheria 4
KG - Kirghizistan 4
NI - Nicaragua 4
PR - Porto Rico 4
UG - Uganda 4
BY - Bielorussia 3
CI - Costa d'Avorio 3
GY - Guiana 3
SV - El Salvador 3
AO - Angola 2
BT - Bhutan 2
Totale 31.356
Salva come PNG Salva come JPEG
Città #
Singapore 2.007
Hong Kong 1.388
Ashburn 1.095
San Jose 1.063
Ann Arbor 987
Fairfield 590
Milan 560
Dublin 558
Woodbridge 491
Ho Chi Minh City 490
Toronto 490
Chandler 466
Dallas 461
Houston 442
Hanoi 427
New York 398
Frankfurt am Main 376
Santa Clara 344
Los Angeles 324
Chicago 313
Wilmington 293
Council Bluffs 270
Princeton 237
Seattle 234
Hefei 227
Beijing 202
Rome 199
Cambridge 196
Jacksonville 196
The Dalles 190
Lauterbourg 136
Dearborn 130
Buffalo 121
Moscow 121
Jakarta 113
Altamura 111
Lawrence 111
Seoul 93
Paris 92
Vienna 88
São Paulo 83
Helsinki 79
Shanghai 79
Columbus 72
San Diego 69
Da Nang 64
Haiphong 61
Tokyo 61
Boardman 59
Nuremberg 56
London 55
Nanjing 53
Montreal 50
Munich 50
Atlanta 45
Dong Ket 44
Warsaw 44
Galati 43
Orem 42
Brooklyn 41
Johannesburg 41
Baghdad 39
Biên Hòa 37
Lachine 37
Tashkent 37
Phoenix 36
Figino 35
Hải Dương 35
Naples 34
Lappeenranta 32
Palermo 32
Brasília 31
Rio de Janeiro 31
Amsterdam 30
Andover 30
Denver 30
Guangzhou 30
Washington 30
Bologna 29
Chennai 29
Salt Lake City 29
Turin 29
Kent 27
Mexico City 26
Pune 26
Quito 26
Quận Bình Thạnh 26
Poplar 25
Stockholm 25
Ha Long 24
Jeddah 24
Belo Horizonte 23
Boston 23
Curitiba 23
Thái Nguyên 23
Vũng Tàu 22
Tampa 21
Ottawa 20
Bogotá 19
Brussels 19
Totale 18.925
Salva come PNG Salva come JPEG
Nome #
Behavioural survey and street-based HIV and HCV rapid testing programme among transgender sex workers 598
Characterizing non-tuberculous mycobacteria infection in bronchiectasis 419
Remdesivir use in patients requiring mechanical ventilation due to COVID-19 413
Unexpected HBV reactivation following discontinuation of antiviral prophylaxis in immunosuppressed subjects with previous HBV exposure 411
Remission of low-grade lymphomatoid granulomatosis with extensive pulmonary involvement following immune restoration via antiretroviral therapy in a newly diagnosed HIV patient 371
Caratteristiche di una coorte di pazienti con co-infezione HIV/HCV: i dati dell’Ambulatorio di Malattie Infettive dell’Ospedale San Gerardo di Monza 362
Effectiveness of dolutegravir-based vs boosted darunavir-based first-line 3-drug regimens in people with HIV with advanced disease: a trial emulation 348
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort 343
The high volume of patients admitted during the SARS-CoV-2 pandemic has an independent harmful impact on in-hospital mortality from COVID-19 342
HPV 16 and 18 contribute to development of anal dysplasia in HIV infection irrespective of gender and sexual orientation 341
Clinical and laboratory predictors of mpox severity and duration: an Italian multicentre cohort study (mpox-Icona) 330
Brief Report: Peripheral Monocyte/Macrophage Phenotypes Associated with the Evolution of Cognitive Performance in HIV-Infected Patients 328
Hepatitis B core antibody positivity is not associated with risk of transaminase elevation following switch to dual antiretroviral therapy 327
Transaminase Decrease Upon Switch From TDF to TAF in PWH Is Modulated by HBV Status 327
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 316
miRNA Expression Profiling in Subcutaneous Adipose Tissue of Monozygotic Twins Discordant for HIV Infection: Validation of Differentially Expressed miRNA and Bioinformatic Analysis 315
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 313
Infezione disseminata da Mycobacterium avium complex con batteriemia persistente in un paziente AIDS-presenter [Disseminated Mycobacterium avium complex infection with persistent bacteremia in an AIDS-presenter patient] 310
Malassorbimento intestinale della terapia antiretrovirale in un paziente affetto da AIDS e micobatteriosi atipica disseminata 303
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting 299
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 296
Brief Report: New HIV Diagnoses in PrEP-Experienced and PrEP-Naive Persons in the ICONA Cohort 290
ECMO: An alternative support for acute respiratory failure caused by tuberculosis? 289
Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients 288
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 282
Regaining virological suppression in a woman living with a six-class resistant HIV by combining injectable antiretroviral drugs guided by genotypic and phenotypic tests 280
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 280
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 271
Influence of efavirenz and 8-hydroxy-efavirenz plasma levels on cognition and central nervous system side effects 260
Neurocognitive Impairment in HIV-Infected Naïve Patients with Advanced Disease: The Role of Virus and Intrathecal Immune Activation 255
Unmasking tuberculosis in the era of antiretroviral treatment 250
High-risk HPV genotypes are associated with anal cytologic abnormalities but not with malignant histological lesions in a cohort of people with HIV (PWH) 249
Lung cryptococcosis in a treated HIV-1-infected patient with suppressed viral load and past disseminated cryptococcosis: Relapse or late IRIS? 249
Nontuberculous Mycobacteria in Noncystic Fibrosis Bronchiectasis 249
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 247
Mycobacterium tuberculosis Beijing family: Analysis of the epidemiological and clinical factors associated with an emerging lineage in the urban area of Milan 246
Awake Prone Positioning in Adults With COVID-19 An Individual Participant Data Meta-Analysis 242
Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice 242
Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study 241
Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances 235
Anti-spike antibody level is associated with the risk of clinical progression among subjects hospitalized with COVID-19 pneumonia: results from a retrospective cohort study 232
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 232
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: A prospective international cohort study 230
Monoclonal antibodies against SARS-CoV-2 to prevent COVID-19 worsening in a large multicenter cohort 228
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 224
Influence of hospitalization upon diagnosis on the risk of tuberculosis clustering 223
Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure 223
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study 222
Determinants of patient and health care services delays for tuberculosis diagnosis in Italy: A cross-sectional observational study 222
Knowledge, Use, and Misuse of Self-Prescribed Doxycycline Postexposure Prophylaxis in a Community-Based Preexposure Prophylaxis Service 222
Long-term durability of dolutegravir + darunavir/cobicistat dual regimen in highly antiretroviral-experienced people living with HIV (DoDaco study) 220
Beware of biases in observational studies on anti-spike monoclonal antibodies 220
COVID-19 Mortality and Stress to the Hospital System From High Patient Load 215
Associations between immune depression and cardiovascular events in HIV infection 209
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 206
Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy 206
Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment 205
A case of mild pulmonary disease due to Mycobacterium shimoidei with a favorable outcome 204
To the editor 204
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 204
Long pentraxin 3 (PTX3) levels predict death, intubation and thrombotic events among hospitalized patients with COVID-19 204
COVID-19 Infection among Incarcerated Individuals and Prison Staff in Lombardy, Italy, March 2020 to February 2021 203
Risk of severe non AIDS events is increased among patients unable to increase their CD4 + T-cell counts >200+/μl despite effective HAART 203
Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013 201
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 200
Pregnant women living with HIV: the experience of IRCCS San Gerardo dei Tintori 197
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 197
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort 196
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort 195
Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: The D:A:D study 195
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 194
Long-term durability of dolutegravir plus darunavir/cobicistat dual regimen in highly antiretroviral-experienced people with HIV (DoDaco study) 194
Do we Still Need Eligibility Criteria to Recommend PrEP? Impact of National Prescribing Requirements on Retention in Care and Sexually Transmitted Infections Acquisition 191
CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load 191
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 189
Cancer incidence in people with HIV in Italy: Comparison of the ICONA COHORT with general population data 186
Pregnancy in women living with HIV: Experience of IRCCS San Gerardo dei Tintori and a narrative review 186
Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration 185
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort) 183
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 180
Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study 180
Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: A comparison of the D: A: D CVD risk equation and general population CVD risk equations 179
Unmasked tuberculosis or lymphoma in late AIDS presenters: A difficult differential diagnosis 178
Heavily treatment-experienced persons living with HIV currently in care in Italy: characteristics, risk factors, and therapeutic options-the ICONA Foundation cohort study 177
Late-Onset Combined Immunodeficiency presenting with Progressive Multifocal Leukoencephalopathy and associated Immune Reconstitution Inflammatory Syndrome 174
Predictors of AIDS-defining events among advanced naïve patients after HAART 174
Imported ciprofloxacin-resistant Neisseria meningitidis 173
Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: The D: A: D study 171
Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress? 170
3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir 170
In-label, off-label prescription, efficacy and tolerability of dalbavancin: report from a National Registry 167
Determinants of worse liver-related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort 165
Mpox Virus in the Pharynx of Men Having Sex with Men: A Case Series 161
Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts >= 200 cells/mm(3) 161
Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: A longitudinal study 159
Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the italian atazanavir expanded access program and master cohorts 159
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 158
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 157
Compassionate Use of Remdesivir in Children With Severe COVID-19 157
Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy 154
Totale 23.922
Salva come PNG Salva come JPEG
Categoria #
all - tutte 114.237
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 114.237
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.325 0 0 368 136 63 111 31 113 58 72 125 248
2022/20232.134 264 585 198 156 141 377 19 114 178 28 50 24
2023/20241.798 62 52 87 47 216 459 356 67 181 54 33 184
2024/20256.379 279 718 595 216 430 244 376 151 458 798 600 1.514
2025/202614.354 1.490 964 1.186 1.321 1.417 716 2.006 611 906 1.180 1.084 1.473
2026/20271.576 546 705 325 0 0 0 0 0 0 0 0 0
Totale 32.187